Core Viewpoint - Baixinan-B (02185) has seen a significant stock price increase of over 10%, currently up 13.5% at HKD 8.83, with a trading volume of HKD 106 million [1] Group 1: Market Developments - Boston Scientific is set to acquire SoniVie for a total price of USD 600 million, actively entering the RDN (Renal Denervation) market by March 2025 [1] - The American College of Cardiology and the American Heart Association updated hypertension treatment guidelines in August, incorporating RDN as a Class IIb recommendation [1] - The Centers for Medicare & Medicaid Services (CMS) proposed a national coverage decision for RDN in July, which, if approved, will significantly accelerate clinical adoption [1] Group 2: Industry Insights - RDN is a new therapeutic device for uncontrolled and resistant hypertension, with the Chinese RDN market expected to exceed RMB 10 billion by 2032 according to Zhi Shi Consulting [1] - Baixinan's Iberis RDN system is the only globally approved device that offers both transradial (TRA) and transfemoral access for RDN, providing a significant first-mover advantage [1] - Strategic partnerships have been established with Yuan Da Health and other international companies to accelerate commercialization, with Germany and France already including Iberis RDN in their healthcare coverage [1]
港股异动 | 百心安-B(02185)再涨超13% RDN年内催化频出 机构称百心安商业化即将加速